First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

06 Oct 2026
First doses of Pixclara administered in Cleveland (OH) and Indianapolis (IN) marking the start of U.S. commercial availability. Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer). Pixclara addresses a significant unmet need helping physicians differentiate
Read More

Notification of cessation of securities - TLX

05 Oct 2026
Read More

Notification regarding unquoted securities - TLX

05 Oct 2026
Read More

Application for quotation of securities - TLX

05 Oct 2026
Read More

FDA Fast Track for BiPASS Pre Biopsy Prostate Imaging

30 Sep 2026
Read More

Change in substantial holding

25 Sep 2026
Read More

Appendix 3Y Change in Director Interest-D Gill

25 Sep 2026
Read More

Application for quotation of securities - TLX

25 Sep 2026
Read More

Grant of waivers of Listing Rule 7.3.4

22 Sep 2026
Read More

Telix + ITM Investor Presentation

21 Sep 2026
Read More
Displaying 1 - 10 of 146